Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance

BACKGROUND: Serum tumour markers, cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) are not routinely recommended for detecting breast cancer recurrence and monitoring treatment. In this study, we aim to evaluate the diagnostic accuracy of absolute CA 15–3 and CEA levels and report on...

Descripción completa

Detalles Bibliográficos
Autores principales: Hing, J.X., Mok, C.W., Tan, P.T., Sudhakar, S.S., Seah, C.M., Lee, W.P., Tan, S.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375621/
https://www.ncbi.nlm.nih.gov/pubmed/32485607
http://dx.doi.org/10.1016/j.breast.2020.05.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375621/
https://www.ncbi.nlm.nih.gov/pubmed/32485607
http://dx.doi.org/10.1016/j.breast.2020.05.005

Ejemplares similares